Table 7– Overview of major bleeding, central nervous system (CNS) and gastrointestinal (GI) bleeding

Author [ref.]	Year	Type	Study	Age years	Subjects n (male %)	OAC	Target INR	Major bleeding^#	CNS %	GI %	Other %
*Wieloch et al. [19]*	2011	AF	National registry	70±12	18 391 (60)	Warfarin	2.0–3.0	2.6 (2.0–3.1)	16	37	47
*Friberg et al. [20]*	2012	AF	National cohort study	74±10	68 306 (59)	Warfarin	NA	1.9	32	NA	68
*DiMarco et al. [21]*	2005	AF	AFFIRM study	70±9	4060 (61)	Warfarin (89%)	2.0–3.0	2.6	23		77
*Pérez-gómez et al. [22]*	2004	AF	NASPEAF	70±7	237 (55)	Acenocoumarol	2.0–3.0	1.8	40	10	50
*Nieto et al. [23]*	2010	VT	RIETE registry	NA	24 395 (NA)	VKA	NA	8.9^¶	25	40	35
*Linkins et al. [24]*	2003	VT	Meta-analysis	NA	10 757 (NA)	VKA	2.0–3.0	7.2	9	NA	91
*Kearon et al. [25]*	2003	VT	RCT	57±16	369 (53)	Warfarin	2.0–3.0	0.9 (0.4–3.0)	22	NA	78

OAC: oral anticoagulation therapy; INR: international normalised ratio; AF: atrial fibrillation; VT: venous thromboembolism; RCT: randomised controlled trial; VKA: vitamin K antagonist; NA: not available. ^#: bleeding rate per 100 patient-years, confidence intervals are provided, where available. ^¶: 546 bleeding events were documented in 90 days.